Conference Service Mandl

abstract: Drug repositioning efforts create alternative development routes for compounds that failed to meet their clinical endpoint but met safety milestones. Repositioning approaches can also be employed for existing drugs to identify alternative uses or new indications. This can involve screening a compound against new targets, or investigating a given target against new indications. Repurposing or repositioning represents both a faster and less risky route to development. A discussion of how to gain access to data, and overcome organizational boundaries will be covered. Case studies that best utilize available technologies to form a comprehensive picture of a compound or target’s potential value will be explored, and will shed light on how to exploit repositioning towards unmet medical need and expanding the drug pipeline. www.healthtech.com

abstract: As internal R&D becomes more strained, most big pharma have refocused on licensing and partnering as an important source of new products to add to their pipelines. This has created an extremely competitive partnering environment requiring strong relationship building, extensive partnership scouting and rapid decision making processes. To achieve these goals, business development executives need to be involved in search and valuations, transactions, alliance management and need to work closely with regulatory departments, intellectual property counsel and R&D.

BioNetwork offers the unique opportunity to meet with an exclusive group of senior decision-makers in private meeting rooms while attending a variety of highly informative presentations and discussions

abstract: With increasing resource pressure, drug developers need to make more effective and informed go/no-go decisions as early as possible in the drug development process. This allows the best compounds to move ahead with adequate resource support. By doing more of the right experiments, earlier in the pre-clinical discovery and development process, drug developers will face fewer surprises as drugs move into the more expensive later stages of the development process. Biomarkers, FDG-PET Imaging, Gene Expression, Metabolic Screening, Protein Tomography and other advanced tools are increasingly being used for early confirmation of a drug development candidate’s ability to reach a target, confirm bioavailability and impact on a target or pathway, to enable an earlier, more effective, decision making processes. Leading drug discovery and development companies are increasingly reorganizing their drug development process and programs to take advantage of these new tools and techniques to improve d

abstract: This course is designed to help chemists understand basic pharmacological principles and the extension of those principles into therapeutic medicine. By the end of this course students should be able to use pharmacology to assess structure-activity data on molecules in biological systems and to see relationships between chemical structure and drug affinity and efficacy.

abstract: This course presents the fundamentals of Pharmacokinetics and Pharmacodynamics as they apply to the chemical structure of drugs. There will be specific discussion of the role of medicinal chemistry in the drug discovery process, how chemical structure affects the absorption, distribution, metabolism and excretion (ADME properties) of drugs and also drug affinity and efficacy (Pharmacodynamics). This course is centered on gaining an understanding of in vitro PK assay data (Caco-2, MDCK, PAMPA, microsomes, hepatocytes etc) to predict in vivo PK and optimize drug ADME properties.

abstract: The purpose of this University of Wisconsin School of Pharmacy five-day short course is to cover practical aspects of dosage form development for preclinical and phase 1 formulations. The formulation approaches include solubilization and disperse phase systems (suspensions, emulsions, microemulsions, liposomes and micelles) for preclinical as well as powders for reconstitution, capsules and tablets for phase 1. The course is a practical guide in that its focus is on major considerations in selecting and evaluating oral dosage forms for preclinical and phase 1 studies by examining the excipients used, their typical level ranges and various preparation/processing procedures on small laboratory and pilot scales. The challenges in developing oral dosage forms at this early stage will be examined in detail, including the major problems encountered and the common strategies that are used to overcome them. This is part of a three course core curriculum on Applied Drug Development.

abstract: Program: Best Practices Virtual Screening Workshop; Docking & Scoring, chaired by Chaya Duraiswami (GlaxoSmithKline), Application of MM-PBSA Free Energy Methods in Drug Discovery, chaired by Judith Lalonde (Bryn Mawr College), Accurate Calculation of pKas, chaired by Paul Labute (Chemical Computing Group), In Silico-based Chemogenomics, chaired by Fabrice Moriaud (MEDIT); PDB Ligands, chaired by Marc Nicklaus (National Institutes of Health); Predictive ADME, chaired by Anthony E. Klon (Pharmacopeia Drug Discovery) and Predictive Toxicology, chaired by Artem Cherkasov (University of British Columbia).

abstract: The program will include: Best Practices Virtual Screening Workshop chaired by Barry Hardy (Douglas Connect), Docking & Scoring, chaired by Chaya Duraiswami (GlaxoSmithKline), Application of MM-PBSA Free Energy Methods in Drug Discovery, chaired by Judith Lalonde (Bryn Mawr College), Accurate Calculation of pKas, chaired by Paul Labute (Chemical Computing Group), In Silico-based Chemogenomics, chaired by Fabrice Moriaud (MEDIT); PDB Ligands: Analysing their Structure & Binding Data, chaired by Marc Nicklaus (National Institutes of Health); Predictive ADME, chaired by Anthony E. Klon (Pharmacopeia Drug Discovery) and Predictive Toxicology, chaired by Artem Cherkasov (University of British Columbia).

abstract: The conference program will include: Systems Biology, chaired by Keith Elliston (Genstruct), Computational Biology, chaired by Debraj Guhathakurta (Merck), Knowledge Management in Translational Medicine, David Bousfield (Ganesha Associates), Applications of Metabolomics to Drug Discovery & Development, chaired by Bruce Kristal (Brigham and Women's Hospital) Predictive ADME, chaired by Anthony E. Klon (Pharmacopeia Drug Discovery) Predictive Toxicology, chaired by Artem Cherkasov (University of British Columbia)

Pre-Conference Workshop, 13 October: Knowledge Management in R&D chaired by John Conway (Accelrys) and Frank Hollinger (FRESH Directions Consulting)

abstract: Latest Advances in Drug Discovery Informatics

abstract: •RNAI For Screening •Kinase Inhibitors •HDAC Inhibitors: Targeting Oncology & Beyond •Oncology Drug Targets-Managing The Portfolio RNAI For Therapeutics •RNAI For Therapeutics www.DiscoveryOnTarget.com

abstract: Molecular imaging techniques especially positron emission tomography (PET) have been increasingly applied in contemporary CNS drug discovery and development. Such techniques allow in the living animal or human subjects the assessment of compound exposure in the CNS, binding to the designated target(s), and the relationship of occupancy and pharmacodynamic effects, as well as the development of biomarkers. Speakers will address advantages and pitfalls, and current methods of molecular imaging for CNS drug discovery and/or development, and provide a range of examples of successful PET tracer development for novel therapeutics.

The BPDG at the New York Academy of Sciences represents a diverse group of scientists and others with an interest in biochemistry, molecular biology, biomedical research, and related areas. Members are from pharmaceutical and biotechnology companies, and university and medical center research facilities across the Eastern United States. The group also serves as the Biochemical Topical Group for the American Chemical Society's New York Section. The purpose of the BPDG is to bring together diverse institutions and communities, industrial and academic, to share new and relevant information at the frontiers of research and development.

abstract: For the past few decades, drug development has been viewed as outside the mission of academic institutions. However, as technology becomes more accessible and as understanding of biological systems increases in its importance for drug discovery, it is now more likely that academic research will have substantial impact on the design of new therapeutics. In the past few years, many universities worldwide have established high-throughput screening cores to facilitate the discovery of small molecule research tools that might eventually be developed into therapeutics. This meeting will address topics important to those who oversee or participate in academic screening programs. There will be a particular emphasis on tools, technologies, and strategies relevant to drug discovery projects initiated in the academic setting.

abstract: Scope of conference – 2007 was a big year for both the implementation and recognition of the value of adaptive trial designs in drug development. This was evidenced by: • Large pharmaceutical organizations implementing and reporting time and cost savings associated with the use of adaptive trial designs • EMEA’s finalization and publication of their “Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with Adaptive Design” (CHMP/EWP/2459/02) last October • EMEA/EFPIA workshop on adaptive designs in confirmatory clinical trials conducted in Dec. 2007 www.healthtech.com

abstract: This primer will provide a current overview of immunology as it applies to cancer etiology, biology and therapy. The target audience for this program is basic and clinical investigators from academic, regulatory, and biopharmaceutical venues. The audience includes clinicians, researchers, students, post-doctoral fellows, and allied health professionals. Topics to be Addressed

* Adoptive T Cell Therapy

* Anti-Angiogenic Therapies

* Antibody Therapy of Cancer

* Approach to Identifying and Therapeutic Exploitation of Tumor Antigens

* Blocking Anti-T Cell Checkpoints

abstract: Drawing on the reputation and expertise of Bio-IT World and Cambridge Healthtech Institute, Bridging Pharma and IT is one of the most influential meetings in North America. It is the only meeting to feature case studies of IT/Science paired discussions that provide insights into cross-domain partnering with an organization's end users and IT. The 2008 agenda will focus on tactics and processes that organizations can effectively and efficiently use to minimize communication gaps between scientists, researchers, and information technology professionals in building solutions and capabilities, utilizing data models and their validation, and integrating drug targets and compounds. A number of joint presentations from pairs of end users and IT and informatics partners will provide indispensable guidance for surmounting challenges and delivering results. www.healthtech.com

abstract: With ten million individuals afflicted each year, no one is entirely immune to cancer and its devastating effects on individuals and families. But recent advances in the development of cancer vaccines - either as therapeutic agents or preventative measures - are hopeful indicators of progress in this field.

This symposium brings together world-renowned researchers and clinicians to shed light on these recent steps forward in cancer studies. Its primary goal is to contribute to the advancement of new immunotherapeutic and preventive approaches for future cancer vaccines.

abstract: The model for new pharmaceutical product development is changing rapidly and your company’s strategy must respond, whether you are a large pharmaceutical company, or an emerging biotech company. Alternative sourcing programs are emerging. Alliances are becoming more and more central to new product development as alliance centric external development programs emerge. Movements towards better integration of business development and alliance management functions and integration of alliances and acquisition, are also transforming how companies are finding, evaluating, structuring and negotiating deals and working with their external partners to develop new products and commercialize those products. Immediately followed by The ASAP-CHI Bio-Pharm Alliance Summit, be part of these premier events! www.healthtech.com

abstract: The model for new pharmaceutical product development is changing rapidly and your company’s strategy must respond, whether you are a large pharmaceutical company, or an emerging biotech company. Alternative sourcing programs are emerging. Alliances are becoming more and more central to new product development as alliance centric external development programs emerge. Movements towards better integration of business development and alliance management functions and integration of alliances and acquisition, are also transforming how companies are finding, evaluating, structuring and negotiating deals and working with their external partners to develop new products and commercialize those products. www.healthtech.com

abstract: Improving products’ effective clinical safety will increase the industry’s fundamental value proposition to patients, healthcare providers, payors and regulators. The program will focus on pharmacovigilance program implementation and specific strategies and approaches to creating true value from a peri- and post-approval drug safety program. Drug safety programs and monitoring and the approach of this conference are not to look at safety in the silos of early-phase safety or post-approval safety but to view safety holistically, across the lifecycle, especially at the transition from approval to broader use in the marketplace. www.healthtech.com

abstract: Each year the Strategic Resource Management attracts over 100 participants who help lead their organization’s resource management strategy. Our 2008 meeting will build on last year’s successful event with novel case studies and perspectives from thought leaders. www.healthtech.com

abstract: •In Vivo Molecular Imaging www.imaging-week.com

abstract: Our 2008 forum will be built with guidance from the PSS advisory board. It will include novel case studies and perspectives from thought leaders who have real-world perspectives to share. www.healthtech.com

abstract: www.healthtech.com

abstract: The course will provide detailed information and the current state-of-the-art knowledge on “must know” topics such as writing SOP’s, the do’s and don’ts for the GLP audit, and Quality Assurance.

Ample time is allocated to each speaker in order to provide an interactive, in-depth tutorial with time for questions, detailed coverage of the subject and discussion of individual problems and situations. The audience will be strongly encouraged to interact, bring problems, discussion points or suggestions in order to brainstorm with the experts and share new information. You will be provided with printed handouts to follow along with the speakers and take notes.

abstract: Welcome to the 3rd annual Stem Cells World Congress. This year's event will be held in beautiful Palm Springs, California - definitely the place to be in January! The conference will be co-located with the World Biobanking Summit. Registered delegates will have access to both meetings ensuring a very cost-effective trip. In addition, it will be immediately followed by LabAutomation 2009. Make the most of your trip by attending the co-located market analysis/business tutorial. Keynote Speakers: Bernard Siegel, Executive Director, Genetics Policy Institute Jan Nolta, Director Stem Cell Programme, University of California Agenda Topics to include: New Advances in Tissue Engineering New Horizons in Regenerative Medicine: Where will the Field be in 20 Years? Regulatory Issues Related to Stem Cell Therapies Stem Cells as Fundamental Tools for Drug Discovery and Disease-Related Research Therapeutic Advances Using Adult Somatic Stem Cells Therapeutic Potential of Pluripotent Human Embryonic and Reprogrammed Somatic Stem Cells

abstract: Welcome to the inaugural World Biobanking Summit. This year's event will be held in beautiful Palm Springs, California - definitely the place to be in January! The conference will be co-located with the Stem Cells World Congress. Registered delegates will have access to both meetings ensuring a very cost-effective trip. In addition, it will be immediately followed by LabAutomation 2009. Agenda Topics to include: Sample Collection & Storage Automation Quality Assurance Bioethics & Regulations Harmonization & Standardization

abstract: The three day forum (January 25-28, 2009 Baltimore, MD) will focus on the latest developments in Process Analytical Technology...emerging techniques, new applications, instrumentation, software, standards, and a look into the future.

abstract: The 2009 Biomanufacturing Summit brings together world class leaders within biopharmaceuticals to explore the dynamic strategies, benchmark the latest technologies and analyze the most cutting edge science sustaining the growth of the biopharmaceutical industry.

abstract: International Online Medical Conference (IOMC 2009) is the 2nd Online Conference on Medicine taking place on March 14 & 15, 2009. It aims to provide a forum for discussing and presenting research findings, studies, and experiences in the field of medicine, to create an opportunity for medical, nursing, and pharmaceutical/pharmacology researchers, students, professors, physicians, practitioners, researchers, executives, scientists, specialists and activists to meet each other online and share their research papers, and to provide a chance to find new research colleagues and partners for future research works.

abstract: Your Next Blockbuster Is Only A Handshake At BioNetwork East 2009:

* Network With Top Decision Makers From Leading Pharmaceutical and Biotech Companies

* Find Specialty Pharmas With The Power To Increase Short And Long-Term Pipelines

* Gain A Sneak Peek Into University-Stage Products Not Yet In The Public Eye

* Form Proactive Alliance Management Tactics For Dealing With Partners In Japan, India And Canada

* Navigate The Changing World Of Regulations, Deal Structures And Contract Legalese

abstract: Digging Into the Deals. Windhover's must-attend event is a Strategic Level Conference On Biopharma Deal Structure and Strategy

abstract: BIO-Windhover continues to be the preferred US-based partnering event for top-level pharmaceutical and biotechnology business development executives and CEOs. At this exclusive conference, attendees will be able to meet one-on-one with other key decision-makers and network with their peers for a more personal experience in an upscale setting.

abstract: Welcome to the Nucleic Acid Diagnostics & Therapeutics Summit. This inaugural summit will be be held in Boston, MA immediately prior to the annual RNAi World Congress, which will address the latest research in RNAi and microRNA research. In contrast the DxRx Summit will be attended by investors, corporate management, business leaders, legal & regulatory advisors, clinical trial CROs and others who are interested in the diagnostic and therapeutic applications of DNA, RNAi, microRNAs, and antisense technology. Registered delegates will also be eligible to attend a half-day interactive business tutorial on the market and business landscape for diagnostics and therapeutics based on RNAi and microRNAs hosted by Enal Razvi, PhD. Agenda Topics to include: Reviews of Company Pipelines Clinical Trial Status of Nucleic Acid-Based Therapeutics Patent Status of Nucleic Acid-Based Diagnostics and Therapeutics Nucleic Acid Drug Delivery microRNAs as Diagnostics and Therapeutic Entities Nucleic Acid Biomarkers for Personalized Medicine Reimbursement and Regulatory Landscape Investor Attitudes to this Sector Emerging Company Showcase Confirmed Speakers: Dr Patrick Y. Lu, President and CEO, Sirnaomics Dr Dmitry Samarsky, VP Technology Development, RXi Pharmaceuticals Dr James Hamilton, CEO, Calando Pharmaceuticals Prof James G Patton, Vanderbilt University Jeffery Vick, CEO, Silence Therapeutics Dr Nobuyoshi Kosaka, National Cancer Center Research Institute, Tokyo Dr Nicolay Ferrari, Director of Pharmacology, Topigen Dr Søren Tulstrup, CEO, Santaris Pharma Dr William Marshall, President and CEO, Miragen Therapeutics